| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
B in Giant Cell Tumor of Bone
From the Department of Orthopaedic Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia
Giant cell tumor of bone (GCT) is a rare primary osteolytic tumor of bone that is characterized by massive tissue destruction at the epiphysis of long bones. There is no evidence that tumor cells themselves are capable of bone destruction; instead, it appears that the tumor cells of GCT act by promoting osteoclastogenesis and, as a consequence, osteoclastic bone resorption. However, the mechanism by which this is achieved is not understood. Here we attempted to determine whether osteoprotegerin ligand (OPGL), the factor that is necessary and essential for osteoclastogenesis, is involved in tumor cell-recruited osteoclast-like giant cell formation in GCT. Using fluorescence in situ hybridization, we sought to determine mRNA expression of OPGL, its receptor RANK, and its decoy receptor OPG in three major cell types of GCT. We demonstrated that OPG mRNA was expressed in all three cell types of GCT, OPGL transcripts were mainly detected in spindle-shaped stromal-like tumor cells, whereas RANK was expressed only in macrophage-like mononuclear cells and multinuclear osteoclast-like giant cells. By semiquantitative RT-PCR, we also showed that the level of OPGL mRNA in GCT is much higher than that in normal bone and osteogenic osteosarcoma. In contrast, a similar level of OPG transcripts was detected in these three kinds of tissues, and RANK mRNA was detectable only in GCT tissues. We have further examined the regulation of gene expression of OPGL and OPG in tumor cells in response to osteotropic hormones. Administration of 1,25(OH)2D3 and dexamethasone resulted in maximum up-regulation of OPGL level and down-regulation of OPG level in cultured GCT stromal-like tumor cells and the mouse bone marrow-derived ST-2 stromal cell line. Furthermore, we have shown that tumor cells of GCT induce differentiation of RANK-expressing myeloid RAW264.7 cells into osteoclast-like cells in the presence of 1,25(OH)2D3 and dexamethasone. Our findings suggest that OPGL is involved in the tumor cell-induced osteoclast-like cell formation in GCT. The ratio of OPGL/OPG by tumor cells may contribute to the degree of osteoclastogenesis and bone resorption.
This article has been cited by other articles:
 |
|
 |
|
  T. Cheng, N. J. Pavlos, C. Wang, J. W.-Y. Tan, J. M. Lin, J. Cornish, M.-H. Zheng, and J. Xu Mutations within the TNF-Like Core Domain of RANKL Impair Osteoclast Differentiation and Activation Mol. Endocrinol., January 1, 2009; 23(1): 35 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sasaki, K. Ishikawa, N. Haraguchi, H. Inoue, T. Ishio, K. Shibata, M. Ohta, S. Kitano, and M. Mori Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis Ann. Surg. Oncol., March 1, 2007; 14(3): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gonzalez-Suarez, D. Branstetter, A. Armstrong, H. Dinh, H. Blumberg, and W. C. Dougall RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini Mol. Cell. Biol., February 15, 2007; 27(4): 1442 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Morgan, G. J. Atkins, M. K. Trivett, S. A. Johnson, M. Kansara, S. L. Schlicht, J. L. Slavin, P. Simmons, I. Dickinson, G. Powell, et al. Molecular Profiling of Giant Cell Tumor of Bone and the Osteoclastic Localization of Ligand for Receptor Activator of Nuclear Factor {kappa}B Am. J. Pathol., July 1, 2005; 167(1): 117 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Pavlos, J. Xu, D. Riedel, J. S. G. Yeoh, S. L. Teitelbaum, J. M. Papadimitriou, R. Jahn, F. P. Ross, and M. H. Zheng Rab3D Regulates a Novel Vesicular Trafficking Pathway That Is Required for Osteoclastic Bone Resorption Mol. Cell. Biol., June 15, 2005; 25(12): 5253 - 5269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Livshits, I Pantsulaia, S Trofimov, and E Kobyliansky Genetic influences on the circulating cytokines involved in osteoclastogenesis J. Med. Genet., June 1, 2004; 41(6): e76 - e76. [Full Text] [PDF]
|
|
|
|
|
|
E. Grimaud, L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau, N. Passuti, F. Gouin, F. Redini, and D. Heymann Receptor Activator of Nuclear Factor {kappa}B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis Am. J. Pathol., November 1, 2003; 163(5): 2021 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Toyomura, Y. Murata, A. Yamamoto, T. Oka, G.-H. Sun-Wada, Y. Wada, and M. Futai From Lysosomes to the Plasma Membrane: LOCALIZATION OF VACUOLAR TYPE H+-ATPase WITH THE a3 ISOFORM DURING OSTEOCLAST DIFFERENTIATION J. Biol. Chem., June 6, 2003; 278(24): 22023 - 22030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Huang, Y Y Cheng, L T C Chow, M H Zheng, and S M Kumta Receptor activator of NF-{kappa}B ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment Mol. Pathol., April 1, 2003; 56(2): 116 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Huang, Y Y Cheng, L T C Chow, M H Zheng, and S M Kumta Tumour cells produce receptor activator of NF-{kappa}B ligand (RANKL) in skeletal metastases J. Clin. Pathol., November 1, 2002; 55(11): 877 - 878. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
